公开(公告)号：WO0102425A3

公开(公告)日：2001-07-12

申请号：PCT/CA0000773

申请日：2000-06-29

Applicant: UNIV HEALTH NETWORK ,  PRIVE GIL

Inventor： PRIVE GIL

IPC: A61K38/16 ,  C07K14/00 ,  C07K14/705

CPC classification number: A61K38/16 ,  C07K14/001 ,  C07K14/705

Abstract: The present invention provides a novel class of detergents referred to herein as lipopeptide detergents. Lipopeptide detergents comprise an amphipathic alpha -helical peptide having a hydrophobic or neutral face and a hydrophilic face. To each end of this peptide is covalently linked an aliphatic hydrocarbon tail, these aliphatic tails being linked thereto such that they associate with the hydrophobic or neutral face of the peptide. Lipopeptide detergents can advantageously be used to stabilize membrane proteins in the absence of a phospholipid bilayer in a manner that preserves the native conformation and permits the subsequent crystallization thereof.

Abstract translation: 本发明提供了一类新型的洗涤剂，在本文中称为脂肽洗涤剂。 脂肽洗涤剂包含具有疏水或中性面和亲水面的两亲α-螺旋肽。 该肽的每个末端与脂肪族烃尾部共价连接，这些脂肪族尾部与其连接，使得它们与肽的疏水或中性面相连。 脂肽洗涤剂可有利地用于在不存在磷脂双分子层的情况下以保留天然构象并允许随后结晶的方式稳定膜蛋白。

公开(公告)号：WO0077031A3

公开(公告)日：2001-04-19

申请号：PCT/CA0000711

申请日：2000-06-15

Applicant: UNIV HEALTH NETWORK ,  GARIEPY JEAN ,  YANG SHAOXIAN

Inventor： GARIEPY JEAN ,  YANG SHAOXIAN

IPC: A61K38/00 ,  C07K7/08 ,  A61P35/00 ,  C07K14/47 ,  C12N15/10

CPC classification number: C07K7/08 ,  A61K38/00

Abstract: Novel ligands that bind to MUC1 are disclosed. The ligands were isolated using an improved phage display technique using MUC1 tandem repeat as a target. Uses of the ligand to detect, monitor or treat cancer as well as to prepare antibodies is also described.

Abstract translation: 公开了结合MUC1的新配体。 使用改进的噬菌体展示技术使用MUC1串联重复作为靶标分离配体。 还描述了配体用于检测，监测或治疗癌症以及制备抗体的用途。

公开(公告)号：WO2015132675A2

公开(公告)日：2015-09-11

申请号：PCT/IB2015001033

申请日：2015-03-06

Applicant: UNIV HEALTH NETWORK

Inventor： MAK TAK W

IPC: A61K39/395

CPC classification number: C12Q1/6883 ,  A61K38/177 ,  A61K39/39541 ,  A61K39/39558 ,  A61K49/0008 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70503 ,  C07K16/2818 ,  C07K2317/76 ,  C12N15/1135 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5088 ,  G01N2333/82 ,  A61K2300/00

Abstract: The present invention is directed to methods and compositions for modulating proteins involved in the immune response. The present invention further provides methods and compositions for treatment of autoimmune disease and cancer by modulating the expression and activity of such proteins.

Abstract translation: 本发明涉及用于调节参与免疫应答的蛋白质的方法和组合物。 本发明还提供了通过调节这些蛋白质的表达和活性来治疗自身免疫疾病和癌症的方法和组合物。

公开(公告)号：WO2013136193A8

公开(公告)日：2014-05-08

申请号：PCT/IB2013001179

申请日：2013-03-14

Applicant: UNIV HEALTH NETWORK ,  TUSCHE MICHAEL W ,  MAK TAK W ,  OHASHI PAMELA S ,  LANG PHILIPP ,  LANG KARL ,  BRENNER DIRK ,  LIN GLORIA

Inventor： TUSCHE MICHAEL W ,  MAK TAK W ,  OHASHI PAMELA S ,  LANG PHILIPP ,  LANG KARL ,  BRENNER DIRK ,  LIN GLORIA

IPC: A61K38/17 ,  A61P3/10 ,  A61P19/02 ,  A61P37/00

CPC classification number: C07K14/70503 ,  A61K38/1709 ,  A61K38/1774 ,  C07K14/705 ,  C07K2319/02 ,  C07K2319/30

Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.

Abstract translation: 本发明还涉及用于调节Toso蛋白质活性的方法和组合物。 本发明还包括使用包含可溶性Toso蛋白的组合物治疗与炎症，自身免疫病和癌症相关的病症。

公开(公告)号：WO2012014146A3

公开(公告)日：2012-05-24

申请号：PCT/IB2011053309

申请日：2011-07-25

Applicant: KONINKL PHILIPS ELECTRONICS NV ,  UNIV HEALTH NETWORK ,  PEKAR VLADIMIR ,  QAZI ARISH ASIF

Inventor： PEKAR VLADIMIR ,  QAZI ARISH ASIF

IPC: G06T7/00

CPC classification number: G06K9/34 ,  G01R33/5608 ,  G06T7/0012 ,  G06T7/143 ,  G06T7/149 ,  G06T2207/10072 ,  G06T2207/10081 ,  G06T2207/10104 ,  G06T2207/10108 ,  G06T2207/10136 ,  G06T2207/20076 ,  G06T2207/20081 ,  G06T2207/30004

Abstract: An imager (10) and a reconstruction processor (12) generate an intensity image (14). A region containing a target volume is identified (20) and limited (24). A classifier (30) operates on the voxels in the limited volume with an enhancement filter to generate an enhanced image, such as an image whose voxel values represent a probability that each voxel is in the target volume. A segmentation processor (40) segments the enhanced image to identify the surface of the target volume to generate a segmented image which is displayed on a monitor (52) or used in a radiation therapy planning system (54).

Abstract translation: 成像器（10）和重建处理器（12）产生强度图像（14）。 识别包含目标体积的区域（20）并限制（24）。 分类器（30）使用增强滤波器对有限体积中的体素进行操作，以生成增强图像，例如其体素值表示每个体素在目标体积中的概率的图像。 分割处理器（40）分割增强图像以识别目标体积的表面，以产生显示在监视器（52）上或在放射治疗计划系统（54）中使用的分割图像）。

公开(公告)号：WO2012000103A1

公开(公告)日：2012-01-05

申请号：PCT/CA2011000776

申请日：2011-07-04

Applicant: UNIV HEALTH NETWORK ,  PAN GUOHUA ,  MASON JACQUELINE M ,  WEI XIN ,  FEHER MIKLOS

Inventor： PAN GUOHUA ,  MASON JACQUELINE M ,  WEI XIN ,  FEHER MIKLOS

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation, hi particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

Abstract translation: 本文提供用于治疗癌症患者的方法，用途和组合物，其中癌症的特征在于PTEN基因突变。在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物，以及鉴定 如果存在PTEN基因突变，则可能对PLK4拮抗剂治疗有反应的患者。

公开(公告)号：WO2008109991A8

公开(公告)日：2008-12-18

申请号：PCT/CA2008000440

申请日：2008-03-06

Applicant: UNIV HEALTH NETWORK ,  PAULS HEINZ W ,  SAMPSON PETER BRENT ,  FORREST BRYAN T ,  LAUFER RADOSLAW ,  LIU YONG ,  FEHER MIKLOS ,  YAO YI ,  PAN GUOHUA

Inventor： PAULS HEINZ W ,  SAMPSON PETER BRENT ,  FORREST BRYAN T ,  LAUFER RADOSLAW ,  LIU YONG ,  FEHER MIKLOS ,  YAO YI ,  PAN GUOHUA

IPC: C07C275/28 ,  A61K31/195 ,  A61K31/34 ,  A61K31/381 ,  A61K31/41 ,  A61K31/44 ,  A61K31/495 ,  A61P35/00 ,  C07C233/52 ,  C07C233/83 ,  C07C237/42 ,  C07C275/06 ,  C07C307/06 ,  C07C307/10 ,  C07C311/19 ,  C07C311/29 ,  C07D213/71 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/44 ,  C07D307/68 ,  C07D307/82 ,  C07D333/34 ,  C07D333/40 ,  C07D401/04 ,  C07D409/06 ,  C07D413/04 ,  C07D413/06 ,  C07D417/04

CPC classification number: C07D409/06 ,  C07C1/26 ,  C07C17/10 ,  C07C2529/40 ,  C07D207/325 ,  C07D213/71 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D263/34 ,  C07D277/48 ,  C07D295/215 ,  C07D307/24 ,  C07D307/68 ,  C07D307/82 ,  C07D333/34 ,  C07D333/40 ,  C07D401/04 ,  C07D405/06 ,  C07D409/04 ,  C07D413/04 ,  C07D413/06 ,  C07D417/04 ,  C07C9/00 ,  C07C19/075

Abstract: A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract translation: CPT抑制剂化合物由结构式（I）或其药学上可接受的盐表示：或其药学上可接受的盐。 药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。 治疗患有癌症的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。

公开(公告)号：WO2007063425A3

公开(公告)日：2007-11-08

申请号：PCT/IB2006003982

申请日：2006-06-15

Applicant: UNIV HEALTH NETWORK ,  KOLIOS MICHAEL ,  CZARNOTA GREGORY J ,  SHERAR MICHAEL D ,  TUNIS ADAM ,  HUNT JOHN W

Inventor： KOLIOS MICHAEL ,  CZARNOTA GREGORY J ,  SHERAR MICHAEL D ,  TUNIS ADAM ,  HUNT JOHN W

IPC: A61B8/00 ,  A61B8/08

CPC classification number: A61B8/08 ,  A61B2090/378 ,  A61F7/00 ,  A61N5/062 ,  A61N5/10

Abstract: A method of detecting cellular damage within a subject comprises transmitting low frequency ultrasound (20MHz or below) into a selected site within the subject wherein the selected site has been exposed to a stress capable of causing cellular death at the selected site. At least a portion of ultrasound backscattered from the ultrasound transmitted into the selected site is received. The received backscattered ultrasound is compared to a control backscatter measurement. An increase or a decrease in intensity or spectral slope of the received backscattered ultrasound when compared to the control backscatter measurement indicates cellular death or damage at the selected site within the subject.

Abstract translation: 检测受试者内的细胞损伤的方法包括将低频超声波（20MHz或更低）发送到受试者内的选定部位，其中所选择的部位已暴露于能够在所选位点引起细胞死亡的应激。 从被发送到所选位置的超声波向后散射的超声波的至少一部分被接收。 将接收的反向散射超声波与控制反向散射测量进行比较。 与控制反向散射测量相比，接收的反向散射超声的强度或光谱斜率的增加或减小表明在受试者内的选定部位处的细胞死亡或损伤。

公开(公告)号：WO2005049082A3

公开(公告)日：2005-11-10

申请号：PCT/EP2004014157

申请日：2004-11-19

Applicant: INST NAT SANTE RECH MED ,  UNIV HEALTH NETWORK ,  SMADJA FLORENCE ,  DICK JOHN E ,  KADOUCHE JEAN

Inventor： SMADJA FLORENCE ,  DICK JOHN E ,  KADOUCHE JEAN

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/02 ,  C12N15/13

CPC classification number: C07K16/2884 ,  A61K2039/505 ,  C07K2317/24

Abstract: The present invention provides two chimeric anti-CD44 antibodies comprising specific animo acid sequence, derived from antibodies A3D8 and H90 and their use, in the preparation of a medicament for eradicating pathological stem cells in cancer therapy, and more specifically in acute myeloid leukaemia therapy.

Abstract translation: 本发明提供了两种衍生自抗体A3D8和H90的特异性阿莫酸序列的嵌合抗CD44抗体及其用于制备用于在癌症治疗中根除病理性干细胞的药物，更具体地说在急性骨髓性白血病治疗中的用途。

公开(公告)号：WO2004026285A3

公开(公告)日：2004-07-29

申请号：PCT/CA0301387

申请日：2003-09-19

Applicant: UNIV HEALTH NETWORK ,  AMGEN CANADA INC ,  CRACKOWER MICHAEL A ,  PENNINGER JOSEF M

Inventor： CRACKOWER MICHAEL A ,  PENNINGER JOSEF M

IPC: A61K31/00 ,  A61K31/343 ,  A61K31/352 ,  A61K31/353 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/585 ,  A61K38/00 ,  A61K38/45 ,  A61P9/00 ,  C12N9/12 ,  C12N9/16 ,  C12N15/85

CPC classification number: C12N15/8509 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0375 ,  A61K31/00 ,  A61K31/343 ,  A61K31/352 ,  A61K31/353 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/585 ,  A61K38/45 ,  C12N9/1205 ,  C12N9/16 ,  C12N2800/30

Abstract: The PTEN/PI3K signaling pathway regulates a vast array of fundamental cellular responses. We show that cardiomyocyte-specific inactivation of tumor suppressor PTEN results in hypertrophy, and unexpectedly, a dramatic decrease in cardiac contractility. Analysis of double mutant mice revealed that the cardiac hypertrophy and the contractility defects can be genetically uncoupled. PI3Kgamma mediates the alteration in cell size while PI3Kgamma acts as a negative regulator of cardiac contractility. Mechanistically, PI3Kgamma inhibits cAMP production and hypercontractility can be reverted by blocking cAMP function. These data show that PTEN has an important in vivo role in cardiomyocyte hypertrophy and GPCR signaling and identify a function for the PTEN-PI3Kgamma pathway in the modulation of heart muscle contractility.

Abstract translation: PTEN / PI3K信号通路调节大量基本的细胞反应。 我们表明，心肌细胞特异性抑制肿瘤抑制剂PTEN导致肥大，并出乎意料地导致心肌收缩力急剧下降。 双突变小鼠的分析表明，心脏肥大和收缩性缺陷可以在遗传上解偶联。 PI3Kgamma介导细胞大小的改变，而PI3Kgamma充当心脏收缩的负调节器。 机械地，PI3Kgamma抑制cAMP产生，并且可以通过阻断cAMP功能来恢复超收缩性。 这些数据表明，PTEN在心肌细胞肥大和GPCR信号传导中具有重要的体内作用，并且在调节心肌收缩力中鉴定PTEN-PI3Kγ途径的功能。